The University of Southampton
University of Southampton Institutional Repository

Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer

Record type: Article

Purpose: To evaluate oral topotecan as single-agent, second-line therapy in patients with ovarian cancer previously treated with a platinum-based regimen.
Patients and Methods: Patients (N = 116) received oral topotecan 2.3 mg/m2 daily for 5 days every 21 days. Eligibility criteria included histologic diagnosis of International Federation of Gynecology and Obstetrics stage III or IV epithelial ovarian cancer, bidimensionally measurable disease, prior platinum-containing chemotherapy, age >= 18 years, performance status <= 2, and life expectancy >= 12 weeks.
Results: Overall response rate was 21.6% (25 of 116 patients). Median duration of response was 25.0 weeks; median time to response was 8.4 weeks. Median time to progression was 14.1 weeks; median survival was 62.2 weeks. Grade 4 neutropenia was experienced by 50.4% of patients in 13.4% of courses administered. Grade 4 thrombocytopenia was experienced by 22.1% of patients in 5.1% of courses. Grade 3 or 4 anemia was experienced by 29.2% of patients in 8.5% of courses. Most frequent nonhematologic toxicities were predominantly (> 90%) grade 1 or 2 and included nausea, alopecia, diarrhea, and vomiting.
Conclusion: Second-line oral topotecan administered at 2.3 mg/m2 for 5 days every 21 days demonstrated activity in patients with progressive or recurrent ovarian cancer after first-line platinum-based chemotherapy. This activity was comparable to that seen in previous studies with intravenous topotecan. Grade 4 neutropenia was less frequent with oral topotecan than previously reported for intravenous topotecan. Oral topotecan is an active, tolerable, and convenient formulation of an established agent for the second-line treatment of advanced epithelial ovarian cancer and may also facilitate exploring prolonged treatment schedules.

Full text not available from this repository.

Citation

Clarke-Pearson, D.L., Van Le, L., Iveson, T., Whitney, C.W., Hanjani, P., Kristensen, G., Malfetano, J.H., Beckman, R.A., Ross, G.A., Lane, S.R., DeWitte, M.H. and Fields, S.Z. (2001) Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer Journal of Clinical Oncology, 19, (19), pp. 3967-3975.

More information

Published date: 2001

Identifiers

Local EPrints ID: 26247
URI: http://eprints.soton.ac.uk/id/eprint/26247
ISSN: 1527-7755
PURE UUID: b2d59e92-a6a6-4cdb-9846-78902c92e6ca

Catalogue record

Date deposited: 21 Apr 2006
Last modified: 17 Jul 2017 16:08

Export record

Contributors

Author: D.L. Clarke-Pearson
Author: L. Van Le
Author: T. Iveson
Author: C.W. Whitney
Author: P. Hanjani
Author: G. Kristensen
Author: J.H. Malfetano
Author: R.A. Beckman
Author: G.A. Ross
Author: S.R. Lane
Author: M.H. DeWitte
Author: S.Z. Fields

University divisions


Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×